Bassiouny Dina, Ismiil Nadia, Dubé Valerie, Han Guangming, Cesari Matthew, Lu Fang-I, Slodkowska Elzbieta, Parra-Herran Carlos, Chiu Hak Fai, Naeim Magda, Li Nim, Khalifa Mahmoud, Nofech-Mozes Sharon
1 Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada.
2 University of Toronto, Toronto, Ontario, Canada.
Int J Surg Pathol. 2018 Jun;26(4):306-317. doi: 10.1177/1066896917752861. Epub 2018 Jan 16.
The distinction of primary mucinous ovarian carcinoma (PMOC) from other primaries or secondaries is essential for selecting therapeutic options and prognostication. We aimed to characterize the immunohistochemical profile of 36 PMOCs using an extended immunohistochemical panel, with clinicopathologic features and outcome. PAX8 was negative in 30 (83.3%), and SATB2 was negative in 32/35. HNF1B, AMACR, and napsin-A were detected in 33 (91.7%), 35 (97.2%), and 0 (0%), respectively. MMR proteins and ARID1A were retained in 100%; PTEN was lost in 4 (11.1%). P53 was aberrant in 10 (27.8%); none overexpressed p16. HER2 was positive in 6/35 (17.1%). Most PMOCs had a favorable outcome. However, recurrence is usually fatal. The typical tumor profile was CK7+, CK20+/-, CDX2+/-, PAX8-, ER-, PgR-, and SATB2-. HER2 positivity suggests a possible target for therapy in advanced disease.
原发性黏液性卵巢癌（PMOC）与其他原发性或继发性肿瘤的鉴别对于选择治疗方案和预后评估至关重要。我们旨在使用扩展的免疫组织化学检测组合来描述36例PMOC的免疫组织化学特征，并分析其临床病理特征和预后。PAX8在30例（83.3%）中呈阴性，SATB2在35例中的32例呈阴性。HNF1B、AMACR和napsin-A的检测阳性率分别为33例（91.7%）、35例（97.2%）和0例（0%）。错配修复蛋白（MMR）和ARID1A均保留，PTEN在4例（11.1%）中缺失。P53在10例（27.8%）中异常；均未过度表达p16。HER2在35例中的6例（17.1%）呈阳性。大多数PMOC预后良好。然而，复发通常是致命的。典型的肿瘤特征为CK7阳性、CK20阳性/阴性、CDX2阳性/阴性、PAX8阴性、雌激素受体（ER）阴性、孕激素受体（PgR）阴性和SATB2阴性。HER2阳性提示晚期疾病可能的治疗靶点。
